DSIP: Sleep Benefits, Reported Doses and Timing
Sleep quality · next-day recovery
People look into DSIP hoping for deeper sleep, fewer awakenings and a more rested morning. Those are useful goals, but the peptide's name does not guarantee any of them.
DSIP, also called emideltide, remains experimental. Small human sleep studies have shown mixed or weak results, with no dependable benefit established for today's marketed under-skin route.
What would better sleep look like?
- Fall asleep more easily
Less time lying awake.
- Stay asleep
Fewer or shorter awakenings.
- Feel rested
Better alertness and functioning the next day.
Reported dose and course
A DSIP guide published by Julian Douwes describes the following example, rechecked October 12, 2026. These are that guide’s reported-use figures, not an approved or proven-effective sleep regimen. Its stronger claims about resetting sleep or avoiding dependence are not established by the controlled trial below.
100–200 mcg
Evening amount
Under the skin in this provider example, not the IV route in the controlled trial.
30–60 min
Before bed
Reported timing, not a verified onset of benefit.
10–14 days
Reported course
Not a proven-effective sleep regimen or a guarantee of lasting improvement.
The historical human study used IV administration, so its exposure and results cannot simply be assigned to the marketed under-skin route. A reported course length does not prove sleep will remain better after the course.
What DSIP is
DSIP grew out of research into sleep-related peptide signaling. “Delta” refers to the slow brain-wave activity associated with deep non-REM sleep. A name based on an early experimental observation is not proof that taking the substance reliably increases restorative sleep in people.
What the controlled sleep study measured
Sleeping differently versus feeling better
| Compare | Objective sleep measures | Subjective sleep measures |
|---|---|---|
| What they describe | Time to fall asleep, time asleep and recorded sleep structure | Perceived sleep quality and next-day tiredness |
| 1992 study signal | Some weak differences in latency and efficiency | No improvement in subjective sleep quality |
| Why both matter | A small laboratory change may not be clinically useful | The treatment should also improve the person’s experience or function |
In that double-blind experiment, patients with chronic insomnia spent five nights in a sleep laboratory. DSIP or placebo was administered intravenously before the final three nights. The investigators judged the significant effects weak and partly attributable to an incidental placebo-group change, concluding that a major short-term therapeutic benefit was unlikely. Original trial.
That is more informative than either “DSIP works” or “DSIP has never been studied.” It also does not validate the subcutaneous route commonly marketed today.
Proposed mechanism: sleep and the HPA axis
Sleep and stress signaling interact, which explains interest in DSIP beyond sedation. But the hypothalamic–pituitary–adrenal (HPA) axis is a system, not evidence that a particular peptide corrects cortisol or hormones. A proposed pathway needs to be connected to a measured clinical benefit in an appropriate trial.
Pharmacokinetics
FDA’s 2026 review describes rapid degradation in the available experiments and a lack of pharmacokinetic evidence for the proposed subcutaneous route. Precise human under-skin half-life and absorption claims should not be inferred from other routes. FDA review.
A second distinction matters: a drug can start a response that lasts after its plasma concentration falls. Therefore, a short half-life alone neither proves an all-night benefit nor disproves one. The plotter’s DSIP curve illustrates its stated assumptions; it cannot predict sleep stages or tell someone when to inject.
What helps when the goal is better sleep?
Describe the actual problem: difficulty falling asleep, repeated waking, an irregular schedule, or unrefreshing sleep despite enough time in bed. A sleep diary can make that discussion more useful than a supplement list. Snoring, witnessed breathing pauses and substantial daytime sleepiness deserve assessment for a sleep disorder.
For chronic insomnia, cognitive behavioral therapy for insomnia (CBT-I) is a recommended first treatment. It is a structured treatment, more than generic “sleep hygiene.” NHLBI treatment guidance.
Frequently asked questions
Are there special benefits for men or women? The studies discussed here do not establish the advertised testosterone, menopause or hormone-balancing claims. A general connection between sleep and hormones is not evidence of those DSIP effects.
Is DSIP an approved sleep medicine? FDA’s 2026 scientific review identifies no FDA-approved drug containing emideltide. A compounding review or advisory vote is a different process from drug approval.
Is DSIP’s long-term safety established? Small, short trials do not establish long-term safety, and their IV experience cannot validate a marketed subcutaneous product.
Is a bedtime subcutaneous dose supported by the IV study? No. Route, exposure and treatment duration differ. The study does not establish the commonly repeated community course.
Was research abandoned because DSIP clears too quickly? That explanation is not demonstrated by the cited evidence. The stronger conclusion is that the available clinical results have not established a reliable treatment benefit.
Related compounds & model context
Article citations are linked in the text. Related catalog entries have separate model inputs and source notes, which may include unverified estimates. See our methodology for model assumptions and limitations.